Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30795377 | 1.00 | GRM2 (1.00) | GRM2 | |
| SCHEMBL742232 | 0.96 | GRM2 (1.00) | GRM2 | |
| SCHEMBL7857222 | 0.96 | GRM2 (1.00) | GRM2 | |
| SCHEMBL744511 | 0.94 | GRM2 (1.00) | GRM2 | |
| SCHEMBL10325109 | 0.90 | GRM2 (1.00) | GRM2 | |
| SCHEMBL10325108 | 0.90 | GRM2 (1.00) | GRM2 | |
| SCHEMBL10325107 | 0.90 | GRM2 (1.00) | GRM2 | |
| SCHEMBL739898 | 0.90 | GRM2 (1.00) | GRM2 | |
| SCHEMBL739767 | 0.87 | GRM2 (1.00) | GRM2 | |
| SCHEMBL740287 | 0.87 | GRM2 (1.00) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085577-B2 | 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-07-21 | — | — | US | claimed |
| CN-102439009-B | 7-aryl-1, 2, 4-triazolo [4,3-a ] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors | ORTHO MCNEIL JANSSEN PHARM | 2014-11-12 | — | — | CN | claimed |
| US-20140200208-A1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ADDEX PHARMA, S.A. (CH) | 2014-07-17 | — | — | US | claimed |
| US-8716480-B2 | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-05-06 | — | — | US | claimed |
| EP-2430021-B1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF mGluR2 RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2013-08-28 | — | — | EP | claimed |
| US-20120184528-A1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ADDEX PHARMA S.A. (CH) | 2012-07-19 | — | — | US | claimed |
| CN-102439009-A | 7-aryl-1, 2, 4-triazolo [4,3-a ] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors | ORTHO MCNEIL JANSSEN PHARM | 2012-05-02 | — | — | CN | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-9085577-B2 | 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2015-07-21 | — | — | US | disclosed |
| CN-102439009-B | 7-aryl-1, 2, 4-triazolo [4,3-a ] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors | ORTHO MCNEIL JANSSEN PHARM | 2014-11-12 | — | — | CN | disclosed |
| US-20140200208-A1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ADDEX PHARMA, S.A. (CH) | 2014-07-17 | — | — | US | disclosed |
| US-8716480-B2 | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2430021-B1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF mGluR2 RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20120184528-A1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ADDEX PHARMA S.A. (CH) | 2012-07-19 | — | — | US | disclosed |
| CN-102439009-A | 7-aryl-1, 2, 4-triazolo [4,3-a ] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors | ORTHO MCNEIL JANSSEN PHARM | 2012-05-02 | — | — | CN | disclosed |
| EP-2430021-A1 | 7-ARYL-1,2,4-TRIAZOLOÝ4,3-A¨PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130423-A1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200208-A1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRIA2 | GRM2 1/4885 |
| US-20120184528-A1 | 7-ARYL-1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRIA2 | GRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.